Our Pipeline
We are a technology-driven company with a proprietary PIV5 vaccine platform. Our pipeline features two clinical stage vaccines and additional vaccines in preclinical development.
COVID-19
Our intranasal COVID vaccine, CVXGA, could produce the mucosal immunity needed to reduce transmission of COVID, as well as help address vaccine hesitancy among people who dislike needles or fear the side effects of existing mRNA-based COVID vaccines. It is well-suited to serve as a booster for previously vaccinated and/or infected people, as well as to serve as a primary vaccine to countries that are struggling to deliver vaccine to their populations.
We have produced COVID vaccines using variant as well as wild-type spike (S) proteins, and demonstrated efficacy against viral challenge in multiple animal species. We have completed a Phase 1 study in adults and teens (NCT04954287), and have initiated a Phase 2 study (NCT05736835).
Respiratory Syncytial Virus (RSV)
RSV is a common respiratory virus that routinely and repeatedly infects people at all ages. It is particularly dangerous for children under 2 years old, and elderly patients with lung disease (e.g. chronic obstructive pulmonary disease). But development of an RSV vaccine for infants and young children has been hampered by the risk of triggering vaccine-enhanced disease with viral antigens, a phenomenon which is not expected with live vaccines.
Our live intranasal RSV vaccines express native full-length F-protein from RSV, which we believe is a superior antigen to “pre-F” or “post-F” protein. FDA has granted Fast Track designation for BLB201, our first RSV vaccine, which is being developed by our affiliate, Blue Lake Biotechnology. A Phase 1 study of BLB201 in adults has been completed (NCT05281263), and a Phase 1/2 study in children is underway (NCT05655182).
Norovirus
Norovirus is the most common cause of acute gastroenteritis worldwide, responsible for outbreaks in long-term care facilities, hospitals, schools, and (notoriously) cruise ships. Transmitted by contaminated food/water or person-to-person contact, it can cause serious medical complications or even death in vulnerable populations like children and the elderly. Each year, there are approximately 20 million infections in the US, resulting in 465,000 ER visits, 190,000 hospitalizations, and 900 deaths.
Lyme Disease
Caused by the bacterium Borrelia burdoferi, and transmitted by ticks of the Ixodes genus, Lyme disease is the most common vector-borne disease in the US. An estimated 476,000 people are diagnosed with and treated for Lyme annually, of which up to 30% develop post-treatment Lyme disease syndrome, suffering from chronic symptoms and significant loss of productivity. With no vaccines on or close to market, Lyme disease presents a prime opportunity to develop a vaccine that can protect the 50 million hikers in the US each year, or the 250 million Americans that live in counties where Lyme ticks have been found.
Additional Programs
Protective efficacy with PIV5-based vaccines has been shown for about 15 different pathogens in multiple animal species, including mice, guinea pigs, hamsters, ferrets, cats, pigs, and monkeys. We continue to test our system against other pathogens in order to select further pipeline programs for development.
CyanVac and Blue Lake Biotechnology Expanded Access Policy (June 2022)
CyanVac and its subsidiary, Blue Lake Biotechnology, are developing prophylactic vaccines for prevention but not treatment of various infectious diseases. As such, we are currently not making our investigational products available on an Expanded Access basis and will only provide them through clinical trials. More information about our ongoing clinical trials is available on this page or at ClinicalTrials.gov.
CyanVac Institutional Financial Conflict of Interest Policy (August 2023)
CyanVac has implemented an FCOI policy relating to its research activities. See full policy here.